Morgan Stanley reaffirmed their overweight rating on shares of Silence Therapeutics ( NASDAQ:SLN – Free Report ) in a report published on Monday, Benzinga reports. The firm currently has a $20.00 price objective on the stock. Silence Therapeutics Stock Up 0.4 % NASDAQ SLN opened at $5.38 on Monday. The firm has a market cap of $161.02 million, a PE ratio of -3.45 and a beta of 0.75. Silence Therapeutics has a one year low of $4.55 and a one year high of $17.99. The stock's 50 day simple moving average is $5.

https://www.dailypolitical.com/2023/07/28/silence-therapeutics-nasdaqsln-receives-overweight-rating-from-morgan-stanley.html

#dailypolitical